Request Demo
Last update 24 May 2025
RO-7428731
Last update 24 May 2025
Overview
Basic Info
Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms RO-7428731, RO7428731 |
Target |
Action stimulants, antagonists |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with RO-7428731NL-OMON54263
AN OPEN-LABEL, MULTICENTER, PHASE I STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY CLINICAL ACTIVITY OF RO7428731 IN PARTICIPANTS WITH GLIOBLASTOMA EXPRESSING MUTANT EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III - EGFRvIII - BP42573
NCT05187624
An Open-label, Multicenter, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III
100 Clinical Results associated with RO-7428731
Login to view more data
100 Translational Medicine associated with RO-7428731
Login to view more data
100 Patents (Medical) associated with RO-7428731
Login to view more data
100 Deals associated with RO-7428731
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glioblastoma Multiforme | Phase 1 | United States | 05 Apr 2022 | |
| Glioblastoma Multiforme | Phase 1 | Australia | 05 Apr 2022 | |
| Glioblastoma Multiforme | Phase 1 | Canada | 05 Apr 2022 | |
| Glioblastoma Multiforme | Phase 1 | Denmark | 05 Apr 2022 | |
| Glioblastoma Multiforme | Phase 1 | Spain | 05 Apr 2022 | |
| Recurrent Glioblastoma | Phase 1 | United States | 05 Apr 2022 | |
| Recurrent Glioblastoma | Phase 1 | Australia | 05 Apr 2022 | |
| Recurrent Glioblastoma | Phase 1 | Canada | 05 Apr 2022 | |
| Recurrent Glioblastoma | Phase 1 | Denmark | 05 Apr 2022 | |
| Recurrent Glioblastoma | Phase 1 | Spain | 05 Apr 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free